These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 16979439)
1. Radioimmunotherapy in a radiation oncology environment: building a multi-specialty team. Macklis RM Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S4-6. PubMed ID: 16979439 [TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists. Macklis RM; Pohlman B Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871 [TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma. Macklis RM Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564 [TBL] [Abstract][Full Text] [Related]
5. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016 [TBL] [Abstract][Full Text] [Related]
6. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Zimmer AM Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740 [TBL] [Abstract][Full Text] [Related]
7. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394 [TBL] [Abstract][Full Text] [Related]
8. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Gordon LI Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400 [TBL] [Abstract][Full Text] [Related]
9. Logistics of therapy with the ibritumomab tiuxetan regimen. Meredith RF Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S35-8. PubMed ID: 16979437 [TBL] [Abstract][Full Text] [Related]
10. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody. Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494 [TBL] [Abstract][Full Text] [Related]
11. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. Marcus R Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024 [TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan. Hendrix CS; de Leon C; Dillman RO Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607 [TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician. Conti PS Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):2-3. PubMed ID: 14762737 [TBL] [Abstract][Full Text] [Related]
14. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. Meredith RF Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435 [TBL] [Abstract][Full Text] [Related]
15. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. Grillo-López AJ Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025 [TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Witzig TE Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175 [TBL] [Abstract][Full Text] [Related]